A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 167 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-13.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.
Among the 11 studies testing elvitegravir in HIV Infections, this one has the largest enrollment, is one of 7 that started in 2013, is one of 7 in phase 3, and was the 6th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9
First in 2007; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,443 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 252 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 3rd largest by enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2013, is one of 26 in phase 3, and was the 68th registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing elvitegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.
Drug: E/C/F/TAF
Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks. Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.
Drug: E/C/F/TDF · Drug: EFV/FTC/TDF · Drug: RTV · Drug: ATV · Drug: FTC/TDF · Drug: COBI
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily
Also known as: EVG/COBI/FTC/TAF; Genvoya®
150/150/200/300 mg FDC tablet administered orally once daily
Also known as: Stribild®
600/200/300 mg FDC tablet administered orally once daily
Also known as: Atripla®
100 mg tablet administered orally once daily
Also known as: Norvir®
300 mg capsule administered orally once daily
Also known as: Reyataz®
200/300 mg tablet administered orally once daily
Also known as: Truvada®
150 mg tablet administered orally once daily
Also known as: Tybost®, GS-9350
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm\^2); the mean (SD) percentage change is presented.
Time frame: Baseline; Week 48
Percent Change From Baseline in Spine BMD at Week 48
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.
Time frame: Baseline; Week 48
Change From Baseline in Serum Creatinine at Week 48
Time frame: Baseline; Week 48
Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48
The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement. EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.
Time frame: Baseline; Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Time frame: Baseline; Week 48
Change From Baseline in CD4 Cell Count at Weeks 96
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Time frame: Baseline; Week 96
Participants were enrolled at study sites in Dominican Republic, Puerto Rico, North America, South America, Europe, Australia, and Asia. The first participant was screened on 27 March 2013. The last study visit occurred on 01 April 2020.
| Milestone | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Started | 963 | 480 |
| Completed | 914 | 445 |
| Not completed | 49 | 35 |
| Withdrew: Withdrew consent | 11 | 17 |
| Withdrew: Lost to follow-up | 10 | 9 |
| Withdrew: Investigator's discretion | 11 | 2 |
| Withdrew: Adverse event | 7 | 4 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Participants randomized and never treated | 4 | 3 |
| Milestone | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Started | 905 | 424 |
| Completed | 854 | 398 |
| Not completed | 51 | 26 |
| Withdrew: Investigator's discretion | 31 | 15 |
| Withdrew: Lost to follow-up | 13 | 9 |
| Withdrew: Withdrew consent | 5 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 1 | 0 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | 95.6 | 92.9 |
| All Participants | 97.2 | 93.1 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm\^2); the mean (SD) percentage change is presented.
| percentage change | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | 1.949 ± 2.9956 | -0.136 ± 2.9890 |
| All Participants | 1.468 ± 2.7136 | -0.340 ± 2.8280 |
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm\^2; the mean (SD) percentage change is presented.
| percentage change | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | 1.861 ± 3.0889 | -0.110 ± 3.7415 |
| All Participants | 1.557 ± 3.8441 | -0.443 ± 4.1387 |
| mg/dL | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | -0.01 ± 0.117 | 0.04 ± 0.123 |
| All Participants | 0.00 ± 0.115 | 0.03 ± 0.105 |
The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement. EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.
| units on a scale | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | -1.6 ± 3.06 | -0.1 ± 2.43 |
| All Participants | -1.5 ± 3.06 | -0.1 ± 2.39 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 | 92.8 | 89.1 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| NDA Data Cut | 92.2 | 90.4 |
| All Participants | 93.5 | 90.4 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 | 90.6 | 85.3 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
| cells/uL | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Baseline (NDA Data Cut) | 712 ± 267.9 | 690 ± 251.4 |
| Change at Week 48 (NDA Data Cut) | 33 ± 166.6 | 27 ± 160.2 |
| Baseline (All Participants) | 701 ± 261.8 | 689 ± 248.0 |
| Change at Week 48 (All Participants) | 35 ± 164.6 | 24 ± 156.1 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
| cells/uL | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) |
|---|---|---|
| Baseline | 701 ± 261.8 | 689 ± 248.0 |
| Change at Week 96 | 60 ± 181.6 | 42 ± 158.0 |
Collected over From the first dose date up to last dose date ( maximum: 307.7 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Phase: E/C/F/TAF | 4/963 (0.4%) | 79/959 (8.2%) | 620/959 (64.7%) |
| Randomized Phase: Stay on Baseline Treatment Regimen (SBR) | 0/480 (0%) | 39/477 (8.2%) | 286/477 (60%) |
| Extension Phase: E/C/F/TAF From E/C/F/TAF | 1/905 (0.1%) | 27/905 (3%) | 298/905 (32.9%) |
| Extension Phase: E/C/F/TAF From SBR | 1/424 (0.2%) | 22/424 (5.2%) | 144/424 (34%) |
| Event | Randomized Phase: E/C/F/TAF | Randomized Phase: Stay on Baseline Treatment Regimen (SBR) | Extension Phase: E/C/F/TAF From E/C/F/TAF | Extension Phase: E/C/F/TAF From SBR |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 5/959 | 0/477 | 0/905 | 2/424 |
| Abdominal painGastrointestinal disorders | 3/959 | 0/477 | 0/905 | 2/424 |
| DiarrhoeaGastrointestinal disorders | 1/959 | 2/477 | 1/905 | 2/424 |
| Chest painGeneral disorders | 1/959 | 0/477 | 0/905 | 2/424 |
| PyrexiaGeneral disorders | 0/959 | 0/477 | 0/905 | 2/424 |
| Myocardial infarctionCardiac disorders | 1/959 | 2/477 | 0/905 | 0/424 |
| CellulitisInfections and infestations | 0/959 | 2/477 | 2/905 | 0/424 |
| InfluenzaInfections and infestations | 0/959 | 2/477 | 0/905 | 0/424 |
| OsteomyelitisInfections and infestations | 1/959 | 2/477 | 0/905 | 0/424 |
| DepressionPsychiatric disorders | 0/959 | 2/477 | 0/905 | 0/424 |
| Event | Randomized Phase: E/C/F/TAF | Randomized Phase: Stay on Baseline Treatment Regimen (SBR) | Extension Phase: E/C/F/TAF From E/C/F/TAF | Extension Phase: E/C/F/TAF From SBR |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 168/959 | 64/477 | 67/905 | 26/424 |
| DiarrhoeaGastrointestinal disorders | 109/959 | 51/477 | 40/905 | 22/424 |
| NasopharyngitisInfections and infestations | 96/959 | 48/477 | 47/905 | 20/424 |
| HeadacheNervous system disorders | 83/959 | 25/477 | 18/905 | 9/424 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 78/959 | 31/477 | 19/905 | 8/424 |
| SyphilisInfections and infestations | 63/959 | 38/477 | 19/905 | 9/424 |
| CoughRespiratory, thoracic and mediastinal disorders | 73/959 | 31/477 | 28/905 | 13/424 |
| InsomniaPsychiatric disorders | 58/959 | 36/477 | 12/905 | 8/424 |
| Back painMusculoskeletal and connective tissue disorders | 70/959 | 33/477 | 30/905 | 9/424 |
| BronchitisInfections and infestations | 69/959 | 26/477 | 17/905 | 13/424 |
Safety Analysis Set included participants who were randomized and received at least one dose of study drug.
| Age, Continuous(Years) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| Mean | 41 ± 10.1 | 41 ± 10.1 | 41 ± 10.1 |
| Sex: Female, Male(Participants) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| Female | 103 | 50 | 153 |
| Male | 856 | 427 | 1283 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 5 | 2 | 7 |
| Race — Asian | 59 | 35 | 94 |
| Race — Black | 169 | 102 | 271 |
| Race — Native Hawaiian or Pacific Islander | 6 | 1 | 7 |
| Race — White | 651 | 314 | 965 |
| Race — Local regulators did not allow collection of race or ethnicity information | 2 | 1 | 3 |
| Race — Other | 67 | 22 | 89 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 248 | 82 | 330 |
| Ethnicity — Not Hispanic or Latino | 709 | 392 | 1101 |
| Ethnicity — Local regulators did not allow collection of race or ethnicity information | 2 | 3 | 5 |
| Region of Enrollment(participants) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| United States | 648 | 316 | 964 |
| United Kingdom | 14 | 8 | 22 |
| Thailand | 35 | 21 | 56 |
| Portugal | 8 | 2 | 10 |
| Switzerland | 5 | 4 | 9 |
| Spain | 5 | 3 | 8 |
| Canada | 51 | 27 | 78 |
| Austria | 16 | 8 | 24 |
| Netherlands | 2 | 3 | 5 |
| Sweden | 1 | 0 | 1 |
| Belgium | 14 | 8 | 22 |
| Brazil | 14 | 5 | 19 |
| Denmark | 1 | 2 | 3 |
| Dominican Republic | 29 | 13 | 42 |
| Italy | 13 | 6 | 19 |
| Mexico | 19 | 6 | 25 |
| Australia | 38 | 22 | 60 |
| France | 12 | 12 | 24 |
| Germany | 34 | 11 | 45 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF | Stay on Baseline Treatment Regimen (SBR) | Total |
|---|---|---|---|
| < 50 copies/mL | 943 | 466 | 1409 |
| ≥ 50 copies/mL | 16 | 11 | 27 |
Showing the first 100 of 167 sites across 20 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Mar 2013 to primary completion in Mar 2015, 23 months.
Results were first posted in Apr 2016, 1 year after primary completion. A results delay was requested in Oct 2014.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 23 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide